Symbols / REPL $7.00 -4.89%
REPL Chart
About
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 578.01M |
| Enterprise Value | 385.22M | Income | -314.85M | Sales | — |
| Book/sh | 2.64 | Cash/sh | 3.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | 479 | IPO | — |
| P/E | — | Forward P/E | -3.49 | PEG | — |
| P/S | — | P/B | 2.65 | P/C | — |
| EV/EBITDA | -1.21 | EV/Sales | — | Quick Ratio | 5.43 |
| Current Ratio | 5.60 | Debt/Eq | 36.26 | LT Debt/Eq | — |
| EPS (ttm) | -3.44 | EPS next Y | -2.01 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-21 | ROA | -43.24% |
| ROE | -90.88% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 82.57M |
| Shs Float | 61.14M | Short Float | 34.45% | Short Ratio | 13.34 |
| Short Interest | — | 52W High | 13.24 | 52W Low | 2.68 |
| Beta | 0.77 | Avg Volume | 1.39M | Volume | 1.18M |
| Target Price | $12.86 | Recom | Buy | Prev Close | $7.36 |
| Price | $7.00 | Change | -4.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$12.86
Mean price target
2. Current target
$7.00
Latest analyst target
3. DCF / Fair value
$-37.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.00
Low
$10.00
High
$19.00
Mean
$12.86
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-05 | main | Piper Sandler | Overweight → Overweight | $14 |
| 2026-02-04 | main | Wedbush | Outperform → Outperform | $19 |
| 2025-11-03 | up | BMO Capital | Underperform → Market Perform | $11 |
| 2025-10-27 | up | HC Wainwright & Co. | Neutral → Buy | $12 |
| 2025-10-20 | up | JP Morgan | Underweight → Neutral | $11 |
| 2025-10-20 | up | Leerink Partners | Market Perform → Outperform | $13 |
| 2025-10-20 | up | Wedbush | Neutral → Outperform | $18 |
| 2025-09-19 | down | JP Morgan | Neutral → Underweight | — |
| 2025-09-08 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-07-30 | up | Cantor Fitzgerald | Neutral → Overweight | — |
| 2025-07-23 | down | BMO Capital | Outperform → Underperform | $2 |
| 2025-07-23 | down | Barclays | Overweight → Equal-Weight | $3 |
| 2025-07-23 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-07-22 | down | Leerink Partners | Outperform → Market Perform | $3 |
| 2025-07-22 | down | JP Morgan | Overweight → Neutral | $9 |
| 2025-07-22 | main | Jefferies | Buy → Buy | $6 |
| 2025-07-22 | down | Wedbush | Outperform → Neutral | $4 |
| 2025-07-16 | main | JP Morgan | Overweight → Overweight | $19 |
| 2025-07-03 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-06-20 | init | Cantor Fitzgerald | — → Overweight | — |
- Replimune Group (NASDAQ:REPL) Stock Price Down 8% - Here's What Happened - MarketBeat Fri, 13 Mar 2026 18
- Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - Yahoo Finance Wed, 31 Dec 2025 08
- Replimune at Leerink, Jefferies investor events March 9–10 - Stock Titan Mon, 02 Mar 2026 08
- Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis Sat, 07 Mar 2026 12
- REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - Zacks Investment Research Wed, 24 Sep 2025 07
- Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire Sat, 20 Sep 2025 07
- $REPL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative hu, 15 Jan 2026 08
- Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz ue, 03 Mar 2026 08
- Replimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade) - Seeking Alpha ue, 21 Oct 2025 07
- Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat Sun, 15 Mar 2026 09
- $REPL stock is up 16% today. Here's what we see in our data. - Quiver Quantitative ue, 28 Oct 2025 07
- Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan Fri, 07 Nov 2025 08
- Replimune Stock: Multiple Shots On Goal But A High Risk Binary Approaches (NASDAQ:REPL) - Seeking Alpha Fri, 20 Feb 2026 08
- Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat Sun, 15 Mar 2026 11
- $REPL stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | — | — | Stock Gift at price 0.00 per share. | ASTLEY-SPARKE PHILIP | Director | — | 2026-02-18 00:00:00 | D |
| 1 | 60000 | — | — | Stock Award(Grant) at price 0.00 per share. | HILL EMILY LUISA | Chief Financial Officer | — | 2025-12-19 00:00:00 | D |
| 2 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | PATEL SUSHIL | Chief Executive Officer | — | 2025-12-19 00:00:00 | D |
| 3 | 60000 | — | — | Stock Award(Grant) at price 0.00 per share. | XYNOS KONSTANTINOS | Officer | — | 2025-12-19 00:00:00 | D |
| 4 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHWENDENMAN ANDREW | Officer | — | 2025-12-19 00:00:00 | D |
| 5 | 35000 | — | — | Stock Award(Grant) at price 0.00 per share. | SARCHI CHRISTOPHER | Officer | — | 2025-12-19 00:00:00 | D |
| 6 | 3169 | 32958 | — | Sale at price 10.40 per share. | DHINGRA KAPIL | Director | — | 2025-12-09 00:00:00 | D |
| 7 | 3169 | 5546 | — | Conversion of Exercise of derivative security at price 1.75 per share. | DHINGRA KAPIL | Director | — | 2025-12-09 00:00:00 | D |
| 8 | 10000 | 111300 | — | Sale at price 11.13 per share. | PATEL SUSHIL | Chief Executive Officer | — | 2025-12-02 00:00:00 | D |
| 9 | 7248 | 65957 | — | Sale at price 9.10 per share. | XYNOS KONSTANTINOS | Officer | — | 2025-11-17 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 4.44M | 4.90M | 20.01K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -256.55M | -229.43M | -177.40M | -114.06M |
| TotalUnusualItems | 21.12M | 23.36M | 10.01M | 390.00K |
| TotalUnusualItemsExcludingGoodwill | 21.12M | 23.36M | 10.01M | 390.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -247.30M | -215.79M | -174.28M | -118.04M |
| ReconciledDepreciation | 3.50M | 2.65M | 2.45M | 2.15M |
| EBITDA | -235.43M | -206.07M | -167.39M | -113.67M |
| EBIT | -238.94M | -208.73M | -169.84M | -115.81M |
| NetInterestIncome | -7.89M | -6.66M | -4.16M | -2.22M |
| InterestExpense | 7.89M | 6.66M | 4.16M | 2.22M |
| NormalizedIncome | -263.98M | -234.25M | -184.27M | -118.43M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -247.30M | -215.79M | -174.28M | -118.04M |
| TotalExpenses | 259.85M | 232.85M | 174.17M | 115.14M |
| TotalOperatingIncomeAsReported | -261.63M | -234.77M | -177.08M | -118.31M |
| DilutedAverageShares | 80.56M | 66.57M | 58.21M | 52.21M |
| BasicAverageShares | 80.56M | 66.57M | 58.21M | 52.21M |
| DilutedEPS | -3.07 | -3.24 | -2.99 | -2.26 |
| BasicEPS | -3.07 | -3.24 | -2.99 | -2.26 |
| DilutedNIAvailtoComStockholders | -247.30M | -215.79M | -174.28M | -118.04M |
| NetIncomeCommonStockholders | -247.30M | -215.79M | -174.28M | -118.04M |
| NetIncome | -247.30M | -215.79M | -174.28M | -118.04M |
| NetIncomeIncludingNoncontrollingInterests | -247.30M | -215.79M | -174.28M | -118.04M |
| NetIncomeContinuousOperations | -247.30M | -215.79M | -174.28M | -118.04M |
| TaxProvision | 468.00K | 408.00K | 288.00K | 0.00 |
| PretaxIncome | -246.83M | -215.39M | -174.00M | -118.04M |
| OtherIncomeExpense | 20.92M | 24.13M | 4.33M | -669.00K |
| OtherNonOperatingIncomeExpenses | -202.00K | 771.00K | -5.68M | -1.06M |
| SpecialIncomeCharges | 0.00 | -913.00K | ||
| OtherSpecialCharges | 913.00K | |||
| GainOnSaleOfSecurity | 21.12M | 23.36M | 10.01M | 390.00K |
| NetNonOperatingInterestIncomeExpense | -7.89M | -6.66M | -4.16M | -2.22M |
| InterestExpenseNonOperating | 7.89M | 6.66M | 4.16M | 2.22M |
| OperatingIncome | -259.85M | -232.85M | -174.17M | -115.14M |
| OperatingExpense | 259.85M | 232.85M | 174.17M | 115.14M |
| OtherOperatingExpenses | -1.77M | -1.92M | -2.91M | -3.17M |
| ResearchAndDevelopment | 189.45M | 174.96M | 126.53M | 79.55M |
| SellingGeneralAndAdministration | 72.18M | 59.81M | 50.55M | 38.77M |
| GeneralAndAdministrativeExpense | 23.20M | |||
| OtherGandA | 23.20M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 77.09M | 61.42M | 56.68M | 47.34M |
| ShareIssued | 77.09M | 61.42M | 56.68M | 47.34M |
| TotalDebt | 76.17M | 75.87M | 60.76M | 32.84M |
| TangibleBookValue | 415.84M | 374.51M | 555.29M | 411.23M |
| InvestedCapital | 462.22M | 419.32M | 583.94M | 411.23M |
| WorkingCapital | 433.52M | 393.23M | 558.78M | 383.22M |
| NetTangibleAssets | 415.84M | 374.51M | 555.29M | 411.23M |
| CapitalLeaseObligations | 29.79M | 31.06M | 32.11M | 32.84M |
| CommonStockEquity | 415.84M | 374.51M | 555.29M | 411.23M |
| TotalCapitalization | 462.22M | 419.32M | 583.94M | 411.23M |
| TotalEquityGrossMinorityInterest | 415.84M | 374.51M | 555.29M | 411.23M |
| StockholdersEquity | 415.84M | 374.51M | 555.29M | 411.23M |
| GainsLossesNotAffectingRetainedEarnings | 5.45M | 4.86M | 5.73M | -973.00K |
| OtherEquityAdjustments | 5.45M | 4.86M | 5.73M | -973.00K |
| RetainedEarnings | -948.58M | -701.28M | -485.49M | -311.20M |
| AdditionalPaidInCapital | 1.36B | 1.07B | 1.03B | 723.36M |
| CapitalStock | 77.00K | 61.00K | 57.00K | 47.00K |
| CommonStock | 77.00K | 61.00K | 57.00K | 47.00K |
| TotalLiabilitiesNetMinorityInterest | 135.49M | 113.21M | 91.30M | 49.96M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 73.12M | 72.78M | 57.47M | 29.21M |
| OtherNonCurrentLiabilities | 941.00K | 786.00K | 472.00K | |
| LongTermDebtAndCapitalLeaseObligation | 72.18M | 71.99M | 57.00M | 29.21M |
| LongTermCapitalLeaseObligation | 25.80M | 27.18M | 28.35M | 29.21M |
| LongTermDebt | 46.38M | 44.81M | 28.65M | |
| CurrentLiabilities | 62.36M | 40.44M | 33.83M | 20.76M |
| OtherCurrentLiabilities | 6.07M | 3.33M | 2.99M | 1.32M |
| CurrentDebtAndCapitalLeaseObligation | 3.98M | 3.88M | 3.76M | 3.63M |
| CurrentCapitalLeaseObligation | 3.98M | 3.88M | 3.76M | 3.63M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 20.08M | 13.91M | 9.91M | 5.57M |
| PayablesAndAccruedExpenses | 32.23M | 19.32M | 17.16M | 10.23M |
| CurrentAccruedExpenses | 19.77M | 16.75M | 11.80M | 6.50M |
| Payables | 12.46M | 2.58M | 5.36M | 3.73M |
| AccountsPayable | 12.46M | 2.58M | 5.36M | 3.73M |
| TotalAssets | 551.33M | 487.72M | 646.59M | 461.19M |
| TotalNonCurrentAssets | 55.45M | 54.05M | 53.99M | 57.22M |
| OtherNonCurrentAssets | 2.90M | 1.70M | 1.64M | 1.64M |
| NetPPE | 52.55M | 52.35M | 52.35M | 55.58M |
| AccumulatedDepreciation | -13.40M | -9.90M | -7.24M | -4.79M |
| GrossPPE | 65.94M | 62.25M | 59.59M | 60.37M |
| Leases | 2.50M | 1.89M | 1.71M | 785.00K |
| ConstructionInProgress | 1.65M | 1.12M | 783.00K | 1.62M |
| OtherProperties | 38.81M | 41.87M | 44.87M | 47.65M |
| MachineryFurnitureEquipment | 22.98M | 17.38M | 12.23M | 10.32M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 495.88M | 433.67M | 592.60M | 403.98M |
| OtherCurrentAssets | 8.35M | 8.08M | 6.28M | 5.27M |
| PrepaidAssets | 5.27M | 4.49M | ||
| Receivables | 3.73M | 4.92M | 2.94M | 3.06M |
| OtherReceivables | 3.73M | 4.92M | 2.94M | 3.06M |
| CashCashEquivalentsAndShortTermInvestments | 483.80M | 420.67M | 583.39M | 395.65M |
| OtherShortTermInvestments | 372.69M | 346.21M | 436.80M | 289.71M |
| CashAndCashEquivalents | 111.12M | 74.46M | 146.59M | 105.95M |
| CashEquivalents | 89.90M | 41.10M | ||
| CashFinancial | 21.22M | 33.36M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -198.94M | -191.13M | -130.32M | -84.52M |
| RepaymentOfDebt | -599.00K | -476.00K | -365.00K | -264.00K |
| IssuanceOfDebt | 0.00 | 15.00M | 28.15M | 0.00 |
| IssuanceOfCapitalStock | 155.73M | 0.00 | 187.29M | 0.00 |
| CapitalExpenditure | -6.69M | -5.66M | -2.27M | -2.34M |
| InterestPaidSupplementalData | 4.20M | 3.04M | 1.07M | 0.00 |
| IncomeTaxPaidSupplementalData | 105.00K | 300.00K | 0.00 | 55.00K |
| EndCashPosition | 112.82M | 76.16M | 148.23M | 107.58M |
| BeginningCashPosition | 76.16M | 148.23M | 107.58M | 184.15M |
| EffectOfExchangeRateChanges | 315.00K | -86.00K | -109.00K | 818.00K |
| ChangesInCash | 36.35M | -71.98M | 40.75M | -77.39M |
| FinancingCashFlow | 252.40M | 16.28M | 311.30M | 6.60M |
| CashFlowFromContinuingFinancingActivities | 252.40M | 16.28M | 311.30M | 6.60M |
| NetOtherFinancingCharges | -895.00K | |||
| ProceedsFromStockOptionExercised | 97.27M | 1.76M | 96.22M | 6.86M |
| NetCommonStockIssuance | 155.73M | 0.00 | 187.29M | 0.00 |
| CommonStockIssuance | 155.73M | 0.00 | 187.29M | 0.00 |
| NetIssuancePaymentsOfDebt | -599.00K | 14.52M | 27.79M | -264.00K |
| NetLongTermDebtIssuance | -599.00K | 14.52M | 27.79M | -264.00K |
| LongTermDebtPayments | -599.00K | -476.00K | -365.00K | -264.00K |
| LongTermDebtIssuance | 0.00 | 15.00M | 28.15M | 0.00 |
| InvestingCashFlow | -23.80M | 97.20M | -142.50M | -1.81M |
| CashFlowFromContinuingInvestingActivities | -23.80M | 97.20M | -142.50M | -1.81M |
| NetInvestmentPurchaseAndSale | -17.11M | 102.86M | -140.23M | 530.00K |
| SaleOfInvestment | 386.48M | 592.38M | 443.18M | 256.25M |
| PurchaseOfInvestment | -403.59M | -489.52M | -583.41M | -255.72M |
| NetPPEPurchaseAndSale | -6.69M | -5.66M | -2.27M | -2.34M |
| PurchaseOfPPE | -6.69M | -5.66M | -2.27M | -2.34M |
| OperatingCashFlow | -192.25M | -185.47M | -128.05M | -82.18M |
| CashFlowFromContinuingOperatingActivities | -192.25M | -185.47M | -128.05M | -82.18M |
| ChangeInWorkingCapital | 20.97M | 2.44M | 12.47M | 4.71M |
| ChangeInOtherWorkingCapital | 2.85M | |||
| ChangeInOtherCurrentLiabilities | -565.00K | -306.00K | 234.00K | -73.00K |
| ChangeInOtherCurrentAssets | -1.20M | 0.00 | 2.65M | 2.53M |
| ChangeInPayablesAndAccruedExpense | 21.68M | 6.44M | 13.36M | 5.84M |
| ChangeInAccruedExpense | 11.74M | 9.23M | 11.38M | 4.72M |
| ChangeInPayable | 9.94M | -2.79M | 1.98M | 1.12M |
| ChangeInAccountPayable | 9.94M | -2.79M | 1.98M | 1.12M |
| ChangeInPrepaidAssets | -252.00K | -1.78M | -1.06M | -815.00K |
| ChangeInReceivables | 1.30M | -1.92M | -61.00K | -247.00K |
| OtherNonCashItems | 4.68M | 4.20M | 3.15M | 2.53M |
| StockBasedCompensation | 35.04M | 34.12M | 28.13M | 24.25M |
| AmortizationOfSecurities | -8.95M | -12.33M | -5.64M | 2.22M |
| DepreciationAmortizationDepletion | 3.50M | 2.65M | 2.45M | 2.15M |
| DepreciationAndAmortization | 3.50M | 2.65M | 2.45M | 2.15M |
| OperatingGainsLosses | -201.00K | -771.00K | 5.68M | 913.00K |
| NetForeignCurrencyExchangeGainLoss | -201.00K | -771.00K | 5.68M | 0.00 |
| NetIncomeFromContinuingOperations | -247.30M | -215.79M | -174.28M | -118.04M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for REPL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|